MAPK3 and colonic neoplasm: In colon cancer cells, exenatide reduced the survival of murine colon cancer cell lines via increased levels of cAMP, which inhibits PI3K/Akt, GSK3, and ERK1/2 and activates pro-apoptotic caspase 3/7 [39].